News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Genmab A/S Announces Partial Clinical Hold on Zalutumumab Studies
June 4, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COPENHAGEN, Denmark, June 3, 2009 (GLOBE NEWSWIRE) -- Summary: Genmab announces that the FDA has placed a partial clinical hold on zalutumumab clinical trials.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Phase II
Europe
MORE ON THIS TOPIC
Neuropsychiatric disorders
Otsuka, Lundbeck’s PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy
July 17, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH EVOTEC
Webinar: Pharma Industry in Crisis
July 16, 2025
·
1 min read
·
BioSpace Insights
Rare diseases
AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials
July 16, 2025
·
1 min read
·
Dan Samorodnitsky
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
July 15, 2025
·
4 min read
·
Tristan Manalac
